Crown Laboratories, Inc. will acquire all outstanding shares of Revance Therapeutics, Inc. common stock in a merger agreement just announced.

Upon completion of the transaction, Crown Laboratories, which owns the PanOxyl line of acne care products, says it expects to be one of the leading global aesthetics and skincare companies, with a portfolio of more than 10 skin health and aesthetic brands.

“This is a significant step forward in Crown’s vision to become a fully integrated global aesthetics and skincare company, bringing innovative solutions to physicians, patients and consumers in the incredibly dynamic aesthetics and skincare market,” said Jeff Bedard, founder and Chief Executive Officer of Crown, in a statement. “Revance has an impressive track record in developing innovative aesthetics offerings that will complement Crown’s innovative line of skincare products. As a combined company, we have the opportunity to create a comprehensive portfolio of high-growth products for all stages of life, and we will be committed to investing in education, training, and practice support for aesthetics providers across the United States.”